SCHEMBL20105040

SCHEMBL20105040

CN1CCN(C(c2ccc(F)cc2)c2c(-c3ccccc3)[nH]c3ccccc23)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
LMNA P02545 2/20 0.52
GAA P10253 1/20 0.52
CNR1 P21554 3/20 0.50
HTR2A P28223 3/20 0.47
CHRM2 P08172 3/20 0.47
ADRA2A P08913 3/20 0.47
CHRM1 P11229 3/20 0.47
DRD1 P21728 3/20 0.47
DRD3 P35462 3/20 0.47
SLC6A3 Q01959 3/20 0.47
KCNH2 Q12809 3/20 0.47
CYP2D6 P10635 3/20 0.47
OPRM1 P35372 2/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM3 P20309 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2C P28335 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20105030 0.92 HTR2A (0.56) MAPTLMNAGAACNR1HTR2A
SCHEMBL21272281 0.91 CHRM2 (0.52) MAPTLMNAGAACNR1HTR2A
SCHEMBL20105038 0.88 CHRM2 (0.60) MAPTLMNACNR1HTR2ACHRM2
SCHEMBL20105041 0.88 CNR1 (0.50) MAPTLMNAGAACNR1HTR2A
SCHEMBL20105014 0.88 CNR1 (0.53) MAPTLMNAGAACNR1HTR2A
SCHEMBL20105020 0.88 HTR2A (0.44) MAPTLMNAGAACNR1HTR2A
SCHEMBL20105028 0.86 CNR1 (0.50) MAPTLMNAGAACNR1CYP2D6
SCHEMBL20105026 0.85 CHRM2 (0.58) MAPTLMNAGAACNR1HTR2A
SCHEMBL20105043 0.81 CHRM2 (0.53) MAPTLMNAGAACNR1HTR2A
SCHEMBL5262177 0.80 MAPT (0.56) MAPTLMNACNR1HTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597362-B2 3-aminoalkylated indole derivative, method for the preparation thereof, and pharmaceutical composition comprising the same SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) 2020-03-24 US claimed
US-20190256465-A1 3-AMINOALKYLATED INDOLE DERIVATIVE, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) 2019-08-22 US claimed
US-10597362-B2 3-aminoalkylated indole derivative, method for the preparation thereof, and pharmaceutical composition comprising the same SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) 2020-03-24 US disclosed
US-20190256465-A1 3-AMINOALKYLATED INDOLE DERIVATIVE, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) 2019-08-22 US disclosed
US-20190256465-A1 3-AMINOALKYLATED INDOLE DERIVATIVE, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) 2019-08-22 US disclosed
WO-2018080215-A1 3-AMINO ALKYLATED INDOLE DERIVATIVE, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597362-B2 3-aminoalkylated indole derivative, method for the preparation thereof, and pharmaceutical composition comprising the same IDO1, TPH1, AADAT MAPT 3118/4885LMNA 2385/4885GAA 3972/4885
US-20190256465-A1 3-AMINOALKYLATED INDOLE DERIVATIVE, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME IDO1, TPH1, AADAT MAPT 3118/4885LMNA 2385/4885GAA 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.